GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab A/S (NAS:GMAB) » Definitions » Total Revenue Growth Rate (Future 3Y To 5Y Est)

Genmab A/S (Genmab A/S) Total Revenue Growth Rate (Future 3Y To 5Y Est) : 23.80 (As of Apr. 28, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Genmab A/S Total Revenue Growth Rate (Future 3Y To 5Y Est)?

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the average growth rate of total revenue estimates over a 3-year to 5-year period.

As of today, Genmab A/S's Total Revenue Growth Rate (Future 3Y To 5Y Est) is 23.80.


Competitive Comparison of Genmab A/S's Total Revenue Growth Rate (Future 3Y To 5Y Est)

For the Biotechnology subindustry, Genmab A/S's Total Revenue Growth Rate (Future 3Y To 5Y Est), along with its competitors' market caps and Total Revenue Growth Rate (Future 3Y To 5Y Est) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genmab A/S's Total Revenue Growth Rate (Future 3Y To 5Y Est) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab A/S's Total Revenue Growth Rate (Future 3Y To 5Y Est) distribution charts can be found below:

* The bar in red indicates where Genmab A/S's Total Revenue Growth Rate (Future 3Y To 5Y Est) falls into.



Genmab A/S  (NAS:GMAB) Total Revenue Growth Rate (Future 3Y To 5Y Est) Explanation

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.

In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.


Genmab A/S Total Revenue Growth Rate (Future 3Y To 5Y Est) Related Terms

Thank you for viewing the detailed overview of Genmab A/S's Total Revenue Growth Rate (Future 3Y To 5Y Est) provided by GuruFocus.com. Please click on the following links to see related term pages.


Genmab A/S (Genmab A/S) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab A/S (NAS:GMAB) » Definitions » Total Revenue Growth Rate (Future 3Y To 5Y Est)
Address
Kalvebod Brygge 43, Copenhagen, DNK, 1560
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab is also the creator of Tepezza for thyroid eye disease (partnered with Horizon) and Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), and Tivdak (partnered with Seagen) for cervical cancer. Genmab has several pipeline candidates targeting other oncologic indications.

Genmab A/S (Genmab A/S) Headlines

From GuruFocus